A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2009
11/17/2009	US7619006 Conjugates with organic acids; uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents; the organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity
11/17/2009	US7619000 S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
11/17/2009	US7618968 Aryl triazines as LPAAT-β inhibitors and uses thereof
11/17/2009	US7618939 Isolated azurin or residues from Pseudomonas aeruginosa; inhibiting development of premalignant lesions; expression vectors; kits
11/17/2009	US7618791 Detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells
11/17/2009	US7618787 Method of screening compound capable of accelerating or inhibiting apoptosis, apoptosis accelarator and apoptosis inhibitor
11/17/2009	US7618785 Diagnostic and therapeutic methods based on the L1 adhesion molecule for ovarian and endometrial tumors
11/17/2009	US7618661 solvent extraction, ultrafiltration, concentrating and drying to obtain an extract powder, irradiating with a far-infrared treatment; remove allergy-inducing agent urushiol; free of allergy side effect; anticarcinogenic agents
11/17/2009	US7618657 For increasing hemoglobin expression level, reactivating fetal or adult hemoglobin, inducing gamma -globin, stimulating cell differentiation, inhibiting malignant cell proliferation, or treating a hemoglobinopathy or a malignant disease
11/17/2009	US7618638 Matrix metalloprotease inhibitor
11/17/2009	US7618633 Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
11/17/2009	US7618629 Manipulation of cytokine levels using CD83 gene products
11/17/2009	US7618621 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
11/17/2009	US7618613 Method for radiolabeling antibodies with yttrium-90
11/17/2009	CA2588495C The utility of uridine nucleosides in the treatment of cachexia
11/17/2009	CA2522051C Diamine derivative, production process therefor and antioxidant
11/17/2009	CA2463272C Piperazine derivatives with ccr1 receptor antagonist activity
11/17/2009	CA2411368C Therapeutic combinations of fatty acids
11/17/2009	CA2411172C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
11/17/2009	CA2396062C Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or t cell subset activity by modulation of xbp-1 activity
11/17/2009	CA2393809C Heterocyclic dihydropyrimidines as potassium channel inhibitors
11/17/2009	CA2374158C Indole derivatives
11/17/2009	CA2369997C Compositions and methods for treating amyloidosis
11/17/2009	CA2301739C Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same
11/17/2009	CA2259583C Azolo triazines and pyrimidines
11/17/2009	CA2230949C Synthetic peptides that inhibit il-6 activity
11/17/2009	CA2166079C Chemically modified oligonucleotide for site-directed mutagenesis
11/17/2009	CA2116327C Method and compositions for cellular reprogramming
11/16/2009	CA2666036A1 Novel compositions and methods for treating hyperproliferative diseases
11/12/2009	WO2009137660A2 Enhancement of drug therapy by mirna
11/12/2009	WO2009137596A1 Substituted amides, method of making, and use as btk inhibitors
11/12/2009	WO2009137471A2 Azo dye related small molecule modulators of protein-protein interactions
11/12/2009	WO2009137391A2 Benzene sulfonamide thiazole and oxazole compounds
11/12/2009	WO2009137378A2 Sequential administration of chemotherapeutic agents for treatment of cancer
11/12/2009	WO2009137201A1 Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
11/12/2009	WO2009137104A1 Combination therapy for breastcancer comprising an antiestrogenic agent
11/12/2009	WO2009137091A2 Catestatin (cst) and its variants for treatment of cardiovascular and metabolic disorders
11/12/2009	WO2009137044A2 Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
11/12/2009	WO2009136995A2 Inhibitors of syk protein kinase
11/12/2009	WO2009136966A1 Inhibitors of protein kinases
11/12/2009	WO2009136663A1 Fused heterocyclic derivatives and use thereof
11/12/2009	WO2009136629A1 Prophylactic/therapeutic agent for lifestyle-related diseases
11/12/2009	WO2009136611A1 Glutathione production enhancer, prophylactic/therapeutic agent for diseases associated with lack of glutathione, and food, beverage and feed
11/12/2009	WO2009136572A1 Polymer conjugate of folic acid or folic acid derivative
11/12/2009	WO2009136501A1 Method and kit for detection of cancer, and therapeutic agent for cancer
11/12/2009	WO2009136396A2 Sulfobetaines for therapy
11/12/2009	WO2009136290A1 Functionalized pyrrolidines and use thereof as iap inhibitors
11/12/2009	WO2009136191A1 Chemical compounds
11/12/2009	WO2009136175A1 Compounds for use in stabilizing p53 mutants
11/12/2009	WO2009136162A1 Intermediate and processes involved in the preparation of 2 ' -cyano-2 ' -de0xy-n4-palmit0yl-1-beta-arabin0furan0sylcytosine
11/12/2009	WO2009136158A1 Preparation of intermediates useful in the syntheis of 2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosylcytosine
11/12/2009	WO2009136144A1 Purine derivatives suitable for the treatment of cancer, autoimmune and inflammatory diseases
11/12/2009	WO2009136007A1 Peptide homing to brain tumors
11/12/2009	WO2009136001A1 Protein kinase modulating agents
11/12/2009	WO2009135939A2 Depsipeptide for use in cancer therapy
11/12/2009	WO2009135614A2 Use of a virus regimen for the treatment of diseases
11/12/2009	WO2009135580A1 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
11/12/2009	WO2009135494A2 Alpha-lactalbumin composition for the treatment of actinic keratosis
11/12/2009	WO2009135352A1 A plum tree extract, a method for preparing the plum tree extract and use thereof
11/12/2009	WO2009135335A1 A method for inactivating mitogen activated protein kinase
11/12/2009	WO2009111691A3 Combination therapy with c-met and egfr antagonists
11/12/2009	WO2009111088A3 Antitumor immunization by liposomal delivery of vaccine to the spleen
11/12/2009	WO2009108838A8 Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1,5-a]pyrimidines, methods for preparation and uses thereof
11/12/2009	WO2009105513A8 Novel compounds and methods for therapy
11/12/2009	WO2009105513A3 Novel compounds and methods for therapy
11/12/2009	WO2009102707A3 Substituted oxazaphosphorines
11/12/2009	WO2009099672A3 Breaking immunological tolerance with a genetically encoded unnatural amino acid
11/12/2009	WO2009098404A3 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof
11/12/2009	WO2009097570A3 Intralymphatic chemotherapy drug carriers
11/12/2009	WO2009087577A3 Barb4 target which comprises tata-binding protein-associated factor 15, antibody designated barb4, barb4 related antibodies, and methods of making and using same
11/12/2009	WO2009067686A3 Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
11/12/2009	WO2009062059A3 Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
11/12/2009	WO2009047323A3 Isoxazole compound for the treatment of cancer
11/12/2009	WO2009043519A3 Use of band 3 protein and pacap-27 as a therapeutic agent
11/12/2009	WO2009043454A3 Use of pacap-27 as a therapeutic agent
11/12/2009	WO2009039976A3 Use of a peptide as a therapeutic agent
11/12/2009	WO2009038779A3 Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
11/12/2009	WO2009033767A3 Use of a peptide as a therapeutic agent
11/12/2009	WO2009033757A3 Use of mage-3 antigen (271-279) as a therapeutic agent
11/12/2009	WO2009033756A3 Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent
11/12/2009	WO2009033750A3 Use of phm-27 alone or in combination with leu-enkephalin as a therapeutic agent
11/12/2009	WO2009033711A3 Use of glp-1 as a therapeutic agent
11/12/2009	US20090281285 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer
11/12/2009	US20090281189 Treprostinil formulation
11/12/2009	US20090281180 Method for enhancing the DNA repair process, treating disorders associated with the DNA repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester
11/12/2009	US20090281172 Bis(thio-hydrazide amide) salts for treatment of cancers
11/12/2009	US20090281164 RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/12/2009	US20090281158 Prodrugs of cc-1065 analogs
11/12/2009	US20090281155 Dimeric Small Molecule Potentiators of Apoptosis
11/12/2009	US20090281147 Method of treating of demyelinating diseases or conditions
11/12/2009	US20090281130 Quinazoline derivatives
11/12/2009	US20090281128 Caspase inhibitors and uses thereof
11/12/2009	US20090281119 Acid addition salts of n-ethyi-n'-[2-methoxy-4-(5-methyi-4-pryimidin-2-yl)phenyl]urea and uses thereof
11/12/2009	US20090281115 Inhibitors of c-kit and uses thereof
11/12/2009	US20090281113 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
11/12/2009	US20090281100 Benzimidazole quinolinones and uses thereof
11/12/2009	US20090281096 Cyclothiocarbamate derivatives as progesterone receptor modulators
11/12/2009	US20090281092 Polo-like kinase inhibitors
11/12/2009	US20090281089 Pyridyl inhibitors of hedgehog signalling
11/12/2009	US20090281086 2 -oxyheteroarylamide derivatives as parp inhibitors

1 ... 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 ... 2211